NCT04003818

Efficacy and Safety of Teicoplanin in CDAD

Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate the safety of teicoplanin in patients with Clostridium difficile infection-associated diarrhea and colitis

Detailed description

Approximate 10 weeks

Conditions

• Clostridium Difficile Infection-associated Diarrhea and Colitis

Interventions

Type	Name	Description
DRUG	TEICOPLANIN	Pharmaceutical form:solution for oral administration Route of administration: oral

Timeline

• Start date: 2020-05-15
• Primary completion: 2021-01-21
• Completion: 2021-03-10
• First posted: 2019-07-01
• Last updated: 2025-09-23

Locations

1 site across 1 country: China